This website has been developed and fully funded by Janssen-Cilag Ltd. and is intended for UK patients prescribed Tremfya®▼ (guselkumab) only.

Information on COVID-19 for patients using Tremfya® (guselkumab)
Access Covid-19

This guidance is correct as of September 2020.

COVID-19: Information for patients prescribed Tremfya® (Guselkumab)

We understand that if you are currently prescribed TREMFYA® (guselkumab) you may have questions about COVID-19 and your treatment. The medical community is still learning about COVID-19, so specific information about the virus and our medicines is not currently available.

If you have any queries in relation to your TREMFYA® medication, you can contact our Medical Information team on 01494 567447 or via email at

Considerations regarding your medication

If you have any questions regarding taking or continuing your medicines in relation to COVID-19, please speak to your doctor or nurse in the first instance.

The current advice is that you should not stop taking your medications or make changes to your medication unless advised to do so by your doctor or nurse (e.g. dermatologist or biologics nurse).1

If you think you may have symptoms of COVID-19, get in touch with your doctor or nurse.

Be aware that you should not use this medication if you have an active infection, including active tuberculosis. If you think you have an infection, or have symptoms of an infection, please contact your doctor, pharmacist or nurse.2 For more information, including some of the signs of infection you should be looking out for during your treatment, please refer to the Patient Information Leaflet (PIL).

Other useful information

For patients living with psoriasis you may wish to visit the COVID-19 information page on the Psoriasis Association UK website.

NHS and UK Government information:

We recommend you also visit the COVID-19 advice page on the NHS website, and follow the NHS guidelines for limiting risk of infection. Further information on UK Government COVID-19 advice, including self-isolation guidance, is also available on the website .

Adverse events should be reported. Reporting forms and information can be found at or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Janssen-Cilag Limited on 01494 567447 or at


  1. St. John’s Institute of Dermatology’s FAQs about immunosuppressive treatments. Available from: [Last accessed October 2020].
  2. Tremfya® Patient Information Leaflet. Available from: [Last accessed October 2020].